Announcements Trials

Browse Landscape

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Pain, Postoperative 3 Neurotoxicity Syndromes 3 Melanoma 3 Leukemia, Myeloid, Acute 3 Brain Neoplasms 3 Recurrence 2 Ovarian Neoplasms 2 Hemorrhage 2 Chronic Pain 2 Agnosia 2 Vulvodynia 1 Uterine Cervical Neoplasms 1 Stomatitis 1 Stomach Neoplasms 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Seizures 1 Radiodermatitis 1 Radiation Injuries 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Postoperative Complications 1 Peripheral Nervous System Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1

Interventions

esmolol 1 epigallocatechin gallate 1 contrast agent BR1 1 alpha-Tocopherol 1 Viusid 1 Sonazoid 1 Sodium Chloride 1 Simvastatin 1 Pentoxifylline 1 Metformin 1 Iodides 1 Everolimus 1 Dietary Supplements 1 Catechin 1 Aspirin 1 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Fibrosis × Sodium Chloride × Clear all

NCT07149506 2025-09-08

OCTOPUS-RD

Universidad de Guanajuato

Phase 3 Enrolling by invitation

Fibrosis, Radiodermatitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡